Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance

被引：33
作者：
Hogan, Jonathan J. [1 ]
Weiss, Brendan M. [2 ]
机构：
[1] Univ Penn, Div Nephrol, Philadelphia, PA 19104 USA
[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
来源：
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2016年 / 11卷 / 09期
关键词：
MULTIPLE-MYELOMA PATIENTS; CHRONIC LYMPHOCYTIC-LEUKEMIA; LENALIDOMIDE PLUS DEXAMETHASONE; MINIMAL RESIDUAL DISEASE; CHAIN DEPOSITION DISEASE; SINGLE-AGENT CARFILZOMIB; MANTLE-CELL LYMPHOMA; TERM-FOLLOW-UP; OPEN-LABEL; FLOW-CYTOMETRY;
D O I：
10.2215/CJN.03160316
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The monoclonal gammopathies of renal significance (MGRS) are a group of disorders characterized by monoclonal Ig deposition in the kidney, but are not associated with systemic lymphoma or overt multiple myeloma. The prevailing hypothesis is that the pathogenic paraproteins in MGRS are produced by underlying B cell or plasma cell clones. However, in the MGRS literature, the yield of detecting a clone has been variable, and progression to ESRD is common. Here, we present an "onco-nephrologic" approach to the MGRS disorders by highlighting recent advances in lymphoma and multiple myeloma that can be used in the evaluation and management of these patients.
引用
收藏
页码：1681 / 1691
页数：11
相关论文
共 65 条
  • [1] A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
    Attal, M
    Harousseau, JL
    Stoppa, AM
    Sotto, JJ
    Fuzibet, JG
    Rossi, JF
    Casassus, P
    Maisonneuve, H
    Facon, T
    Ifrah, N
    Payen, C
    Bataille, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) : 91 - 97
  • [2] Results of autologous stem cell transplant in multiple myeloma patients with renal failure
    Badros, A
    Barlogie, B
    Siegel, E
    Roberts, J
    Langmaid, C
    Zangari, M
    Desikan, R
    Shaver, MJ
    Fassas, A
    McConnell, S
    Muwalla, F
    Barri, Y
    Anaissie, E
    Munshi, N
    Tricot, G
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (04) : 822 - 829
  • [3] Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
    Badros, A. Z.
    Vij, R.
    Martin, T.
    Zonder, J. A.
    Kunkel, L.
    Wang, Z.
    Lee, S.
    Wong, A. F.
    Niesvizky, R.
    [J]. LEUKEMIA, 2013, 27 (08) : 1707 - 1714
  • [4] Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits
    Bhutani, Gauri
    Nasr, Samih H.
    Said, Samar M.
    Sethi, Sanjeev
    Fervenza, Fernando C.
    Morice, William G.
    Kurtin, Paul J.
    Buadi, Francis K.
    Dingli, David
    Dispenzieri, Angela
    Gertz, Morie A.
    Lacy, Martha Q.
    Kapoor, Prashant
    Kumar, Shaji
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Leung, Nelson
    [J]. MAYO CLINIC PROCEEDINGS, 2015, 90 (05) : 587 - 596
  • [5] Clinical practice:: Monoclonal gammopathy of undetermined significance
    Blade, Joan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (26) : 2765 - 2770
  • [6] Diagnosis of monoclonal gammopathy of renal significance
    Bridoux, Frank
    Leung, Nelson
    Hutchison, Colin A.
    Touchard, Guy
    Sethi, Sanjeev
    Fermand, Jean-Paul
    Picken, Maria M.
    Herrera, Guillermo A.
    Kastritis, Efstathios
    Merlini, Giampaolo
    Roussel, Murielle
    Fervenza, Fernando C.
    Dispenzieri, Angela
    Kyle, Robert A.
    Nasr, Samih H.
    [J]. KIDNEY INTERNATIONAL, 2015, 87 (04) : 698 - 711
  • [7] Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
    Byrd, JC
    Murphy, T
    Howard, RS
    Lucas, MS
    Goodrich, A
    Park, K
    Pearson, M
    Waselenko, JK
    Ling, G
    Grever, MR
    Grillo-Lopez, AJ
    Rosenberg, J
    Kunkel, L
    Flinn, IW
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) : 2153 - 2164
  • [8] Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
    Byrd, John C.
    Furman, Richard R.
    Coutre, Steven E.
    Burger, Jan A.
    Blum, Kristie A.
    Coleman, Morton
    Wierda, William G.
    Jones, Jeffrey A.
    Zhao, Weiqiang
    Heerema, Nyla A.
    Johnson, Amy J.
    Shaw, Yun
    Bilotti, Elizabeth
    Zhou, Cathy
    James, Danelle F.
    O'Brien, Susan
    [J]. BLOOD, 2015, 125 (16) : 2497 - 2506
  • [9] Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study
    Chanan-Khan, Asher
    Miller, Kena C.
    Musial, Laurie
    Lawrence, David
    Padmanabhan, Swaminathan
    Takeshita, Kenichi
    Porter, Carl W.
    Goodrich, David W.
    Bernstein, Zale P.
    Wallace, Paul
    Spaner, David
    Mohr, Alice
    Byrne, Catriona
    Hernandez-Ilizaliturri, Francisco
    Chrystal, Cynthia
    Starostik, Petr
    Czuczman, Myron S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) : 5343 - 5349
  • [10] Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study
    Chanan-Khan, Asher A.
    Kaufman, Jonathan L.
    Mehta, Jayesh
    Richardson, Paul G.
    Miller, Kena C.
    Lonial, Sagar
    Munshi, Nikhil C.
    Schlossman, Robert
    Tariman, Joseph
    Singhal, Seema
    [J]. BLOOD, 2007, 109 (06) : 2604 - 2606
1234567